ATAXIN-1は,そのネイティブ複合体内の抑制剤Capicuaと相互作用し,SCA1神経病理を引き起こす
Yung C Lam1, Aaron B Bowman, Paymaan Jafar-Nejad
1Department of Neuroscience, Baylor College of Medicine, Houston, TX 77030, USA.
Cell
|December 28, 2006
まとめ
スピノセレベラーアタクシア1型 (SCA1) は,拡張したATAXIN-1 (ATXN1) から生じる. この研究は,ATXN1を明らかにしています.
科学分野:
- 神経生物学 神経生物学とは
- 分子遺伝学 分子遺伝学
- 神経変性疾患 神経変性疾患とは
背景:
- Spinocerebellar ataxia type 1 (SCA1) は,ATXN1タンパク質のポリグルタミン経路拡張に関連した神経変性疾患である.
- SCA1の病原性における重要な質問は,拡張されたATXN1が新しい相互作用または強化された野生型の機能を通じて毒性を引き起こすかどうかです.
研究 の 目的:
- 野生型および拡張型ATAXIN-1 (ATXN1) のタンパク質相互作用を調査する.
- ATXN1媒介の神経毒性におけるCapicuaの役割を決定する スピノセレベラーアタキア1型 (SCA1) の神経毒性.
主な方法:
- マウスの小脳から溶解可能なタンパク質複合体の分析.
- ドロソフィラと哺乳類の細胞で,ATXN1がCapicuaと結合するインビトロおよびインビボの研究.
- ATXN1-Capicuaの相互作用と神経毒性に対するS776A変異の効果の評価.
主要な成果:
- ワイルド型と拡張型の両方ATXN1は,トランスクリプション抑制体Capicua.と大きく安定した複合体を形成する.
- ATXN1は,キャピュアの活動に直接結合し,調節し,その安定状態レベルに影響を与えます.
- ATXN1の神経毒性を防ぐ変異 (S776A) は,Capicua.との関連性を大幅に減少させます.
結論:
- ATXN1のネイティブ機能は,Capicuaとの相互作用を伴い,その抑制活性を調節します.
- SCA1の神経病理は,異常な新しい相互作用ではなく,ATXN1のネイティブの相互作用,特にCapicuaとの相互作用の増強に依存しているようです.
- これらの発見は,ATXN1の機能とSCA1.1の基礎となる分子機構に関する重要な洞察を提供します.
関連する概念動画
01:33Pleiotropy
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
01:19Allosteric Proteins-ATCase
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...